Mixed lineage kinases activate MEK independently of RAF to mediate resistance to RAF inhibitors

Nature Communications

Volumn 5, Issue , 2014, Pages

  Marusiak, Anna A ^a   Edwards, Zoe C ^a   Hugo, Willy ^b   Trotter, Eleanor W ^a   Girotti, Maria R ^a   Stephenson, Natalie L ^a   Kong, Xiangju ^b   Gartside, Michael G ^c   Fawdar, Shameem ^a   Hudson, Andrew ^a   Breitwieser, Wolfgang ^a   Hayward, Nicholas K ^c   Marais, Richard ^a   Lo, Roger S ^b   Brognard, John ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; ANTHRA[1,9 CD]PYRAZOL 6(2H) ONE; ARGININE; B RAF KINASE; B RAF KINASE INHIBITOR; CASPASE 3; DABRAFENIB; L 779450; L779450; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE KINASE 4; MITOGEN ACTIVATED PROTEIN KINASE KINASE 7; MIXED LINEAGE KINASE; MIXED LINEAGE KINASE 1; MIXED LINEAGE KINASE 2; MIXED LINEAGE KINASE 3; MIXED LINEAGE KINASE 4; N [3 (5 CHLORO 1H PYRROLO[2,3 B]PYRIDINE 3 CARBONYL) 2,4 DIFLUOROPHENYL]PROPANESULFONAMIDE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; SELUMETINIB; SORAFENIB; STRESS ACTIVATED PROTEIN KINASE; TETRACYCLINE; UNCLASSIFIED DRUG; VALINE; VEMURAFENIB; INDOLE DERIVATIVE; MITOGEN ACTIVATED PROTEIN KINASE KINASE; MITOGEN ACTIVATED PROTEIN KINASE KINASE KINASE; PROTEIN KINASE INHIBITOR; SULFONAMIDE;

CELL ORGANELLE; DRUG RESISTANCE; ENZYME ACTIVITY; GENETIC ANALYSIS; INHIBITOR; MUTATION; NUMERICAL MODEL; SURVIVAL;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER GROWTH; CANCER RESISTANCE; CELL DEATH; CELL SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; ENZYME ACTIVATION; FEMALE; GAIN OF FUNCTION MUTATION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MELANOMA; MELANOMA CELL LINE; MOUSE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; SKIN CARCINOGENESIS; TREATMENT RESPONSE; TUMOR SUPPRESSOR GENE; TUMOR XENOGRAFT; UPREGULATION; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL LINE; DISEASE MODEL; DRUG EFFECTS; DRUG RESISTANCE; GENETICS; METABOLISM; MUTATION; PHOSPHORYLATION;

ANIMALS; CELL LINE; CELL SURVIVAL; DISEASE MODELS, ANIMAL; DRUG RESISTANCE, NEOPLASM; ENZYME ACTIVATION; HUMANS; INDOLES; MAP KINASE KINASE KINASES; MAP KINASE SIGNALING SYSTEM; MICE; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; MUTATION; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS B-RAF; SULFONAMIDES; UP-REGULATION;

EID: 84901330364     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms4901     Document Type: Article

References (36)

1. Gallo, K. A. & Johnson, G. L. Mixed-lineage kinase control of JNK and p38 MAPK pathways. Nat. Rev. Mol. Cell Biol. 3, 663-672 (2002). (Pubitemid 34987787)
2. Chadee, D. N. & Kyriakis, J. M. MLK3 is required for mitogen activation of B-Raf, ERK and cell proliferation. Nat. Cell Biol. 6, 770-776 (2004). (Pubitemid 39144483)
3. Chadee, D. N. et al. Mixed-lineage kinase 3 regulates B-Raf through maintenance of the B-Raf/Raf-1 complex and inhibition by the NF2 tumor suppressor protein. Proc. Natl Acad. Sci. USA 103, 4463-4468 (2006).
4. Kant, S. et al. TNF-stimulated MAP kinase activation mediated by a Rho family GTPase signaling pathway. Genes Dev. 25, 2069-2078 (2011).
5. Bardelli, A. et al. Mutational analysis of the tyrosine kinome in colorectal cancers. Science 300, 949 (2003). (Pubitemid 36548874)
6. Velho, S. et al. Mixed lineage kinase 3 gene mutations in mismatch repair deficient gastrointestinal tumours. Hum. Mol. Genet. 19, 697-706 (2010).
7. Martini, M. et al. Mixed lineage kinase MLK4 is activated in colorectal cancers where it synergistically cooperates with activated RAS signaling in driving tumorigenesis. Cancer Res. 73, 1912-1921 (2013).
8. Stark, M. S. et al. Frequent somatic mutations in MAP3K5 and MAP3K9 in metastatic melanoma identified by exome sequencing. Nat. Genet. 44, 165-169 (2012).
9. Cerami, E. et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2, 401-404 (2012).
10. Gao, J. et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci. Signal. 6, pl1 (2013).
11. Hodis, E. et al. A landscape of driver mutations in melanoma. Cell 150, 251-263 (2012).
12. Krauthammer, M. et al. Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma. Nat. Genet. 44, 1006-1014 (2012).
13. Davies, H. et al. Mutations of the BRAF gene in human cancer. Nature 417, 949-954 (2002). (Pubitemid 34716871)
14. Wan, P. T. et al. Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell 116, 855-867 (2004). (Pubitemid 38410730)
15. Wellbrock, C., Karasarides, M. & Marais, R. The RAF proteins take centre stage. Nature reviews. Mol. Cell Biol. 5, 875-885 (2004). (Pubitemid 39486539)
16. Flaherty, K. T. et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N. Engl. J. Med. 363, 809-819 (2010).
17. Sosman, J. A. et al. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N. Engl. J. Med. 366, 707-714 (2012).
18. Nazarian, R. et al. Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature 468, 973-977 (2010).
19. Shi, H. et al. Melanoma whole-exome sequencing identifies (V600E)B-RAF amplification-mediated acquired B-RAF inhibitor resistance. Nat. Commun. 3, 724 (2012).
20. Straussman, R. et al. Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion. Nature 487, 500-4c (2012).
21. Su, F. et al. Resistance to selective BRAF inhibition can be mediated by modest upstream pathway activation. Cancer Res. 72, 969-978 (2012).
22. Su, F. et al. RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors. N Engl. J. Med. 366, 207-215 (2012).
23. Villanueva, J. et al. Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K. Cancer Cell 18, 683-695 (2010).
24. Wilson, T. R. et al. Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors. Nature 487, 505-509 (2012).
25. Girotti, M. R. et al. Inhibiting EGF receptor or SRC family kinase signaling overcomes BRAF inhibitor resistance in melanoma. Cancer Discov. 3, 158-167 (2013).
26. Shi, H. et al. A novel AKT1 mutant amplifies an adaptive melanoma response to BRAF inhibition. Cancer Discov. 4, 69-79 (2014).
27. Shi, H. et al. Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy. Cancer Discov. 4, 80-93 (2014).
28. Fawdar, S. et al. Targeted genetic dependency screen facilitates identification of actionable mutations in FGFR4, MAP3K9, and PAK5 in lung cancer. Proc. Natl. Acad. Sci. USA 110, 12426-12431 (2013).
29. Le, K., Blomain, E. S., Rodeck, U. & Aplin, A. E. Selective RAF inhibitor impairs ERK1/2 phosphorylation and growth in mutant NRAS, vemurafenib-resistant melanoma cells. Pigment Cell Melanoma Res. 26, 509-517 (2013).
30. Rizos, H. et al. BRAF inhibitor resistance mechanisms in metastatic melanoma: spectrum and clinical impact. Clin. Cancer Res. 20, 1965-1977 (2014).
31. Johannessen, C. M. et al. COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature 468, 968-972 (2010).
32. Lacroix, M. MDA-MB-435 cells are from melanoma, not from breast cancer. Cancer Chemother. Pharmacol. 63, 567-567 (2009).
33. Little, A. S., Smith, P. D. & Cook, S. J. Mechanisms of acquired resistance to ERK1/2 pathway inhibitors. Oncogene 32, 1207-1215 (2012).
34. Poulikakos, P. I. et al. RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E). Nature 480, 387-390 (2011).
35. Workman, P. et al. Guidelines for the welfare and use of animals in cancer research. Br. J. Cancer 102, 1555-1577 (2010).
36. Arnold, K., Bordoli, L., Kopp, J. & Schwede, T. The SWISS-MODEL workspace: a web-based environment for protein structure homology modelling. Bioinformatics 22, 195-201 (2006). (Pubitemid 43205406)